Polymyxin B: A new strategy for multidrug-resistant Gram-negative organisms

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 661-668

  Yuan, Zhe ^a   Tam, Vincent H ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Gram negative bacteria; Multidrug resistance; Polymyxin B

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHOLESTEROL; DEXTRAN 70; DIPALMITOYLPHOSPHATIDYLCHOLINE; IMMUNOGLOBULIN; INTERLEUKIN 6; LIPOSOME; POLYMYXIN B; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; APNEA; BACTEREMIA; BACTERIAL INFECTION; BLOOD TOXICITY; BRONCHOSPASM; CELLULITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; COUGHING; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENCAPSULATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; INJECTION SITE PAIN; LOADING DRUG DOSE; LUNG INFECTION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PERITONITIS; PHARMACODYNAMICS; PNEUMONIA; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SEPTIC SHOCK; TRACHEOBRONCHITIS; URINARY TRACT INFECTION; WOUND INFECTION; ANIMAL; DRUG EFFECT; GRAM NEGATIVE INFECTION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXIN B;

EID: 44449094697     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.661     Document Type: Review

References (43)

1. Kwa A, Kasiakou SK, Tam VH, et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21
2. Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve Clin J Med 2007;74:S12-20
3. Bratu S, Quale J, Cebular S, et al. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005;24:196-201
4. Zavascki AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007;60:1206-15
5. Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46
6. Falagas ME, Rafailidis PI. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock 2007;27:605-9
7. Yang QW, Xu YC, Chen MJ, et al. Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005. Zhonghua Yi Xue Za Zhi 2007;87:2753-8
8. Holloway KP, Rouphael NG, Wells JB et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939-45
9. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001 - 2004). Clin Microbiol Infect 2006;12:315-21
10. CLSI. Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement M 100 - S16. Wayne, Pennsylvania, USA; 2006
11. Hogardt M, Schmoldt S, Götzfried M, et al. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004;54:1057-61
12. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90
13. Arroyo LA, García-Curiel A, Pachón-Ibañez ME, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005;43:903-5
14. Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008;60(2):163-7
15. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624-30
16. Furtado GH, d'Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30:315-9
17. Teng CB, Koh PT, Lye DC, et al. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 2008;31:80-2
18. Ouderkirk JP, Nord JA, Turett GS, et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62
19. Parchuri S, Mohan S, Cunha BA. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfittly with polymyxin B. Heart Lung 2005;34:360-3
20. Sarria JC, Angulo-Pernett F, Kimbrough RC, et al. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis 2004;23:340-1
21. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-9
22. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007;58:235-40
23. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007;29:9-25
24. Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-7
25. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetbacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006;5:10
26. Ostronoff M, Ostronoff F, Sucupira A, et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis 2006;10:339-40
27. LaPorte DC, Rosenthal KS, Storm DR. Inhibition of Escherichia coli growth and respiration by polymyxin B covalently attached to agarose beads. Biochemistry 1977;16:1642-8
28. Brown MR, Watkins WM. Low magnesium and phospholipid content of well walls of Pseudomonas aeruginosa resistant to polymyxin. Nature 1970;227:1360-1
29. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003;50:205-17
30. Lacour S, Doublet P, Obadia B, et al. A novel role for protein-tyrosine kinase Etk from Escherichia coli K-12 related to polymyxin resistance. Res Microbiol 2006;157:637-41
31. Bhor VM, Thomas CJ, Surolia N, et al. Polymyxin B: an ode to an old antidote for endoroxic shock. Mol Biosyst 2005;1:213-22
32. Baldwin G, Alpert G, Caputo GL, et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis 1991;164:542-9
33. Flynn PM, Shenep JL, Stokes DC, et al. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicaemia. J Infect Dis 1987;156:706-12
34. Guo YB, Chen LP, Cao HW, et al. Polymyxin B antagonizing biological activity of lipopolysaccharide. J Traumatol 2007;10:180-3
35. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47
36. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
37. Orwa JA, Van Gerven A, Roets E, et al. Liquid chromatography of polymyxin B sulphate. J Chromatogr A 2000;870:237-43
38. Ko KS, Sub JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7
39. Landman D, Bratu S, Alam M, et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55:954-7
40. Alipour M, Halwani M, Omri A, et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gramnegative bacterial strains. Int J Pharm 2008; In press
41. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002;64:1407-13
42. Pattani AS, Mandawgade SD, Patravale V.B. Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of Polymyxin B. J Nanosci Nanotechnol 2006;6:2986-90
43. Lyons JM, Davis C, Rieman MT, et al. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children. J Burn Care Res 2006;27:813-8